GEN Exclusives

More »

GEN News Highlights

More »
Mar 19, 2008

AstraZeneca Taps Cenix for RNAi Drug Discovery

  • Cenix BioScience will help AstraZeneca advance discovery activities and validate drug targets. Cenix will combine high-throughput (HT) applications of RNAi-based gene silencing with high-content phenotypic analyses in cultured human cells.

    The initial project will involve an HT-RNAi screen using an assay strategy codesigned with AstraZeneca to discover and validate oncology targets. Cenix will use Definiens’ Cellenger image-analysis platform to implement multiparametric microscopy-based assays. The company reports that this will lead to insights into cellular functions and loss-of-function phenotypes of analyzed genes.

    Cenix hopes to expand the collaboration beyond oncology into multiple projects, says Christophe Echeverri, CEO and CSO.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?